Leustatin (Cladribine)

Cladribine is a purine nucleoside analog that is taken up by lymphocytes and phosphorylated to an active triphosphate. This metabolite incorporates into DNA, halting synthesis and triggering programmed cell death, which selectively depletes proliferating malignant or autoreactive lymphocytes.

The dosing regimen for Leustatin is individualized by the prescribing physician based on the specific indication, patient characteristics, and clinical response. Healthcare professionals determine the appropriate dose, schedule, and duration according to approved guidelines and patient monitoring.

Safety data for cladribine in pregnancy and lactation are limited. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk. Patients should discuss family planning and breastfeeding considerations with their healthcare provider.

To request Leustatin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Compared with conventional chemotherapy, cladribine offers a targeted mechanism that preferentially depletes lymphocytes, often resulting in a different toxicity profile. While other agents may cause broader cytotoxic effects, cladribine’s selective action can lead to fewer off‑target side effects but requires careful monitoring of immune function.

Leustatin must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. Keep the product in its original packaging until use and ensure that temperature monitoring is maintained throughout transport and storage.

Leustatin is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional in a clinical setting, following aseptic technique and the prescribed infusion rate. The exact infusion schedule is determined by the treating physician.

The most serious risks include severe infections due to profound lymphopenia, opportunistic infections, autoimmune hepatitis, tumor lysis syndrome, and the rare possibility of secondary malignancies. Patients should be monitored closely for signs of infection, liver dysfunction, and metabolic disturbances.

Leustatin is contraindicated in patients with active severe infections, those receiving live vaccines, individuals with profound immunosuppression, and patients with known hypersensitivity to cladribine or any formulation excipients. Clinicians must evaluate each patient’s medical history before initiating therapy.